临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
6期
1037-1039,1040
,共4页
超广谱β-内酰胺酶%大肠埃希菌%临床情况%耐药性
超廣譜β-內酰胺酶%大腸埃希菌%臨床情況%耐藥性
초엄보β-내선알매%대장애희균%림상정황%내약성
extended spectrum β-lactamases%Escherichia coli%clinical conditions%drug resistance
目的：了解产超广谱β-内酰胺酶( ESBLs)大肠埃希菌( ECO)在我院2008-2012年的临床分布和耐药情况。方法采用VITEK-Compact系统和Phoenix 100系统进行细菌鉴定，稀释法进行体外抗菌药物敏感试验。结果临床分离ECO 630株，其中产ESBLs的ECO菌363株，总产酶率为57．62%。产ESBLs的ECO标本呼吸道最多(44．63%)，其次是尿液(33．61%)、血液(7．44%)等，科室分布依次是重症监护室(31．13%)，其次为妇产科(9．09%)，心脏外科(9．09%)。药敏结果显示：产ESBLs的ECO对临床常用抗菌药物均产生了严重耐药性，对亚胺培南高度敏感，对哌拉西林/他唑巴坦及阿米卡星耐药率较低，对大多数抗菌药物的耐药率明显高于非产ESBLs株，差异有统计学意义( P<0．05)。结论产ESBLs的ECO菌检出率呈逐年上升趋势，产ESBLs的ECO对临床常用抗菌药物均产生了严重耐药性，在治疗ECO时应根据实验室结果合理选用抗菌药物。
目的：瞭解產超廣譜β-內酰胺酶( ESBLs)大腸埃希菌( ECO)在我院2008-2012年的臨床分佈和耐藥情況。方法採用VITEK-Compact繫統和Phoenix 100繫統進行細菌鑒定，稀釋法進行體外抗菌藥物敏感試驗。結果臨床分離ECO 630株，其中產ESBLs的ECO菌363株，總產酶率為57．62%。產ESBLs的ECO標本呼吸道最多(44．63%)，其次是尿液(33．61%)、血液(7．44%)等，科室分佈依次是重癥鑑護室(31．13%)，其次為婦產科(9．09%)，心髒外科(9．09%)。藥敏結果顯示：產ESBLs的ECO對臨床常用抗菌藥物均產生瞭嚴重耐藥性，對亞胺培南高度敏感，對哌拉西林/他唑巴坦及阿米卡星耐藥率較低，對大多數抗菌藥物的耐藥率明顯高于非產ESBLs株，差異有統計學意義( P<0．05)。結論產ESBLs的ECO菌檢齣率呈逐年上升趨勢，產ESBLs的ECO對臨床常用抗菌藥物均產生瞭嚴重耐藥性，在治療ECO時應根據實驗室結果閤理選用抗菌藥物。
목적：료해산초엄보β-내선알매( ESBLs)대장애희균( ECO)재아원2008-2012년적림상분포화내약정황。방법채용VITEK-Compact계통화Phoenix 100계통진행세균감정，희석법진행체외항균약물민감시험。결과림상분리ECO 630주，기중산ESBLs적ECO균363주，총산매솔위57．62%。산ESBLs적ECO표본호흡도최다(44．63%)，기차시뇨액(33．61%)、혈액(7．44%)등，과실분포의차시중증감호실(31．13%)，기차위부산과(9．09%)，심장외과(9．09%)。약민결과현시：산ESBLs적ECO대림상상용항균약물균산생료엄중내약성，대아알배남고도민감，대고랍서림/타서파탄급아미잡성내약솔교저，대대다수항균약물적내약솔명현고우비산ESBLs주，차이유통계학의의( P<0．05)。결론산ESBLs적ECO균검출솔정축년상승추세，산ESBLs적ECO대림상상용항균약물균산생료엄중내약성，재치료ECO시응근거실험실결과합리선용항균약물。
Objective To investigate the clinical distribution and drug resistance of ESBLs-producing Esche-richia coli from 2008 to 2012 in our hospital. Methods The bacteria were identified by VITEK-compact system and Phoenix 100 system, and drug resistance test was performed by dilution method. Results 630 strains of Escherichia coli were isolated from clinical specimens, and the ESBLs-producing strains in Escherichia coli was 363. The detec-tion rate of ESBLs-producing Escherichia coli was 57. 62%. The source of specimens were mostly from respiratory tract(44. 63%), followed by urine (33. 61%) and blood (7. 44%). The distribution of department was 31. 13% in ICU, 11. 5% in Obstetrics and Gynecology and 17% in cardiac surgery ward. The drug susceptibility testing result showed that the ESBLs-producing E. coli strains showed severe resistance to commonly used antibiotics, but were highly sensitive to imipenem and low resistance rate to piperacillin/tazobactam and amikacin. The drug resistance of the ESBLs-producing strains to most antibiotics was significantly higher than those of non ESBLs-producing strains. Conclusion The detection rate of ESBLs-producing E. coli increases year by year. The ESBLs-producing E. coli strains show severe resistance to commonly used antibiotics, which should be chosen according to the results of drug susceptibility test.
